Concepts (230)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Extracellular Matrix Proteins | 5 | 2015 | 78 | 0.800 |
Why?
|
| Transforming Growth Factor beta | 5 | 2015 | 216 | 0.750 |
Why?
|
| Gaucher Disease | 1 | 2016 | 3 | 0.500 |
Why?
|
| Proteoglycans | 3 | 2014 | 49 | 0.450 |
Why?
|
| Long-Term Potentiation | 2 | 2005 | 109 | 0.400 |
Why?
|
| Transforming Growth Factor beta1 | 3 | 2009 | 97 | 0.380 |
Why?
|
| Estradiol | 1 | 2014 | 268 | 0.370 |
Why?
|
| Transcription, Genetic | 2 | 2014 | 592 | 0.350 |
Why?
|
| Osteosarcoma | 1 | 2009 | 30 | 0.300 |
Why?
|
| Bone Neoplasms | 1 | 2009 | 49 | 0.290 |
Why?
|
| Extracellular Matrix | 3 | 2004 | 131 | 0.280 |
Why?
|
| Versicans | 6 | 2010 | 8 | 0.260 |
Why?
|
| Peptide Fragments | 1 | 2009 | 307 | 0.260 |
Why?
|
| Chondrocytes | 4 | 2014 | 15 | 0.250 |
Why?
|
| Apoptosis | 3 | 2015 | 1568 | 0.250 |
Why?
|
| Fibroblasts | 4 | 2016 | 281 | 0.220 |
Why?
|
| Electroencephalography | 1 | 2005 | 139 | 0.210 |
Why?
|
| Cell-Matrix Junctions | 1 | 2003 | 2 | 0.200 |
Why?
|
| Theta Rhythm | 1 | 2003 | 11 | 0.200 |
Why?
|
| Hippocampus | 2 | 2005 | 594 | 0.200 |
Why?
|
| Oligopeptides | 1 | 2003 | 109 | 0.190 |
Why?
|
| Animals | 15 | 2016 | 16992 | 0.170 |
Why?
|
| Muscle, Skeletal | 1 | 2003 | 316 | 0.160 |
Why?
|
| Cell Adhesion | 5 | 2003 | 238 | 0.160 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 760 | 0.150 |
Why?
|
| Cell Line | 3 | 2015 | 1410 | 0.140 |
Why?
|
| Integrins | 2 | 2009 | 54 | 0.120 |
Why?
|
| Pyrrolidines | 1 | 2016 | 31 | 0.120 |
Why?
|
| Exons | 2 | 2014 | 92 | 0.120 |
Why?
|
| Dogs | 1 | 2016 | 204 | 0.120 |
Why?
|
| Kinetics | 1 | 2016 | 695 | 0.110 |
Why?
|
| 5' Flanking Region | 1 | 2014 | 5 | 0.110 |
Why?
|
| Papio | 1 | 2014 | 22 | 0.110 |
Why?
|
| Retroviridae | 1 | 2014 | 25 | 0.110 |
Why?
|
| Enzyme Inhibitors | 1 | 2016 | 458 | 0.110 |
Why?
|
| Response Elements | 1 | 2014 | 55 | 0.100 |
Why?
|
| Amino Acid Sequence | 2 | 2009 | 1180 | 0.100 |
Why?
|
| Conserved Sequence | 1 | 2014 | 122 | 0.100 |
Why?
|
| Oxidative Stress | 2 | 2010 | 1003 | 0.100 |
Why?
|
| Genes, Reporter | 1 | 2014 | 148 | 0.100 |
Why?
|
| Electric Stimulation | 2 | 2005 | 186 | 0.100 |
Why?
|
| Alternative Splicing | 1 | 2014 | 94 | 0.100 |
Why?
|
| Genetic Vectors | 1 | 2014 | 165 | 0.100 |
Why?
|
| Cell Culture Techniques | 1 | 2014 | 152 | 0.100 |
Why?
|
| RNA, Messenger | 3 | 2014 | 1271 | 0.100 |
Why?
|
| Analysis of Variance | 3 | 2010 | 575 | 0.100 |
Why?
|
| Transfection | 1 | 2014 | 532 | 0.100 |
Why?
|
| Estrogens | 1 | 2014 | 203 | 0.090 |
Why?
|
| Retina | 1 | 2015 | 289 | 0.090 |
Why?
|
| Endothelial Cells | 1 | 2015 | 329 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 1 | 2014 | 526 | 0.090 |
Why?
|
| Computer Simulation | 1 | 2014 | 408 | 0.090 |
Why?
|
| Gene Expression Regulation, Developmental | 2 | 2003 | 300 | 0.090 |
Why?
|
| Macrophages | 1 | 2015 | 529 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2010 | 934 | 0.080 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2010 | 44 | 0.080 |
Why?
|
| Humans | 12 | 2016 | 43102 | 0.080 |
Why?
|
| Macrophages, Peritoneal | 1 | 2009 | 23 | 0.080 |
Why?
|
| Receptors, LDL | 1 | 2009 | 42 | 0.070 |
Why?
|
| Hypercholesterolemia | 1 | 2009 | 42 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2005 | 1766 | 0.070 |
Why?
|
| Prostatic Hyperplasia | 1 | 2009 | 32 | 0.070 |
Why?
|
| Cells, Cultured | 4 | 2009 | 1621 | 0.070 |
Why?
|
| Cell Line, Tumor | 3 | 2010 | 2676 | 0.070 |
Why?
|
| Proteomics | 1 | 2010 | 378 | 0.070 |
Why?
|
| Rats | 3 | 2005 | 3735 | 0.070 |
Why?
|
| Female | 8 | 2014 | 24698 | 0.070 |
Why?
|
| Kidney Diseases | 1 | 2009 | 172 | 0.070 |
Why?
|
| Atherosclerosis | 1 | 2009 | 169 | 0.060 |
Why?
|
| Interleukin-1beta | 1 | 2007 | 75 | 0.060 |
Why?
|
| Cycloheximide | 2 | 2003 | 30 | 0.060 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2007 | 91 | 0.060 |
Why?
|
| Fibronectins | 2 | 2003 | 69 | 0.060 |
Why?
|
| Mice | 4 | 2009 | 6644 | 0.060 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 415 | 0.060 |
Why?
|
| Biocompatible Materials | 2 | 2004 | 108 | 0.060 |
Why?
|
| Stromal Cells | 2 | 2004 | 55 | 0.060 |
Why?
|
| Polyesters | 2 | 2004 | 28 | 0.060 |
Why?
|
| Texas | 1 | 2008 | 457 | 0.060 |
Why?
|
| Protein Binding | 1 | 2009 | 1082 | 0.060 |
Why?
|
| Mexican Americans | 1 | 2008 | 226 | 0.060 |
Why?
|
| Procollagen N-Endopeptidase | 1 | 2005 | 1 | 0.060 |
Why?
|
| Extracellular Space | 1 | 2005 | 36 | 0.060 |
Why?
|
| Polyethylene Glycols | 2 | 2004 | 108 | 0.060 |
Why?
|
| Disintegrins | 1 | 2005 | 3 | 0.060 |
Why?
|
| Hydrogels | 2 | 2004 | 59 | 0.060 |
Why?
|
| Metalloendopeptidases | 1 | 2005 | 15 | 0.060 |
Why?
|
| Ovulation | 1 | 2005 | 21 | 0.060 |
Why?
|
| Excitatory Postsynaptic Potentials | 1 | 2005 | 80 | 0.060 |
Why?
|
| Electrophysiology | 1 | 2005 | 138 | 0.060 |
Why?
|
| Breast Neoplasms | 3 | 2014 | 1723 | 0.060 |
Why?
|
| Male | 6 | 2009 | 23409 | 0.050 |
Why?
|
| Rural Population | 1 | 2008 | 373 | 0.050 |
Why?
|
| Ovarian Follicle | 1 | 2005 | 44 | 0.050 |
Why?
|
| Tenascin | 1 | 2004 | 5 | 0.050 |
Why?
|
| Chondroitin Sulfates | 1 | 2004 | 11 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2004 | 57 | 0.050 |
Why?
|
| Oocytes | 1 | 2005 | 149 | 0.050 |
Why?
|
| Bone Marrow Cells | 1 | 2004 | 79 | 0.050 |
Why?
|
| Hyaluronic Acid | 1 | 2004 | 36 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2008 | 734 | 0.050 |
Why?
|
| Embryonic and Fetal Development | 1 | 2003 | 32 | 0.050 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2003 | 35 | 0.050 |
Why?
|
| Edetic Acid | 1 | 2003 | 23 | 0.050 |
Why?
|
| Histocytochemistry | 1 | 2003 | 47 | 0.050 |
Why?
|
| Collagen Type I | 1 | 2003 | 35 | 0.050 |
Why?
|
| Myoblasts | 1 | 2003 | 30 | 0.050 |
Why?
|
| Mesoderm | 1 | 2003 | 73 | 0.050 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 138 | 0.050 |
Why?
|
| Laminin | 1 | 2003 | 58 | 0.050 |
Why?
|
| Organ Specificity | 1 | 2003 | 141 | 0.050 |
Why?
|
| Muscle Development | 1 | 2003 | 51 | 0.050 |
Why?
|
| Muscle Fibers, Skeletal | 1 | 2003 | 70 | 0.050 |
Why?
|
| Cell Adhesion Molecules | 1 | 2003 | 83 | 0.050 |
Why?
|
| Prevalence | 1 | 2008 | 1612 | 0.050 |
Why?
|
| Antibodies | 1 | 2003 | 144 | 0.050 |
Why?
|
| Cytological Techniques | 1 | 2002 | 14 | 0.050 |
Why?
|
| Neuronal Plasticity | 1 | 2003 | 126 | 0.040 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 518 | 0.040 |
Why?
|
| Blotting, Western | 1 | 2003 | 883 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 3 | 2015 | 1869 | 0.040 |
Why?
|
| Molecular Sequence Data | 1 | 2003 | 1542 | 0.040 |
Why?
|
| Time Factors | 3 | 2014 | 1857 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2015 | 2157 | 0.040 |
Why?
|
| Risk Factors | 1 | 2008 | 3994 | 0.040 |
Why?
|
| Lectins, C-Type | 3 | 2004 | 37 | 0.040 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 652 | 0.030 |
Why?
|
| Up-Regulation | 2 | 2010 | 536 | 0.030 |
Why?
|
| Mice, Knockout | 2 | 2015 | 1035 | 0.030 |
Why?
|
| Middle Aged | 3 | 2008 | 12222 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2015 | 1596 | 0.030 |
Why?
|
| Adult | 3 | 2008 | 13872 | 0.030 |
Why?
|
| Reproducibility of Results | 2 | 2014 | 1081 | 0.030 |
Why?
|
| Retinal Vessels | 1 | 2015 | 29 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 2015 | 139 | 0.030 |
Why?
|
| Prostatic Neoplasms | 1 | 2003 | 1092 | 0.030 |
Why?
|
| Disease-Free Survival | 2 | 2004 | 116 | 0.020 |
Why?
|
| Culture Media, Conditioned | 2 | 2003 | 49 | 0.020 |
Why?
|
| Lymph Nodes | 2 | 2004 | 74 | 0.020 |
Why?
|
| Molecular Weight | 2 | 2003 | 168 | 0.020 |
Why?
|
| Cartilage, Articular | 2 | 2002 | 12 | 0.020 |
Why?
|
| Rabbits | 2 | 2003 | 278 | 0.020 |
Why?
|
| Stress, Mechanical | 2 | 2003 | 164 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2003 | 508 | 0.020 |
Why?
|
| Rotenone | 1 | 2010 | 17 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 43 | 0.020 |
Why?
|
| Heat-Shock Proteins | 1 | 2010 | 57 | 0.020 |
Why?
|
| Cricetulus | 1 | 2010 | 82 | 0.020 |
Why?
|
| Insecticides | 1 | 2010 | 54 | 0.020 |
Why?
|
| CHO Cells | 1 | 2010 | 123 | 0.020 |
Why?
|
| Cricetinae | 1 | 2010 | 241 | 0.020 |
Why?
|
| Endoplasmic Reticulum | 1 | 2010 | 108 | 0.020 |
Why?
|
| Caspase 3 | 1 | 2010 | 227 | 0.020 |
Why?
|
| Neuroblastoma | 1 | 2010 | 136 | 0.020 |
Why?
|
| Streptozocin | 1 | 2009 | 26 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2009 | 25 | 0.020 |
Why?
|
| Urinalysis | 1 | 2009 | 34 | 0.020 |
Why?
|
| Proteome | 1 | 2010 | 152 | 0.020 |
Why?
|
| Neovascularization, Pathologic | 1 | 2010 | 139 | 0.020 |
Why?
|
| Probability | 1 | 2009 | 82 | 0.020 |
Why?
|
| Sulfhydryl Compounds | 1 | 2009 | 51 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2010 | 290 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 458 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2010 | 374 | 0.020 |
Why?
|
| Chemotaxis | 1 | 2009 | 68 | 0.020 |
Why?
|
| Random Allocation | 1 | 2009 | 147 | 0.020 |
Why?
|
| Glycosaminoglycans | 1 | 2009 | 24 | 0.020 |
Why?
|
| Organ Size | 1 | 2009 | 170 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2009 | 196 | 0.020 |
Why?
|
| Prostatectomy | 1 | 2009 | 70 | 0.020 |
Why?
|
| Cohort Studies | 2 | 2004 | 1759 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2009 | 457 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2009 | 131 | 0.020 |
Why?
|
| Prostate | 1 | 2009 | 155 | 0.020 |
Why?
|
| Sulfur Radioisotopes | 1 | 2007 | 8 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 1124 | 0.020 |
Why?
|
| Sulfates | 1 | 2007 | 26 | 0.020 |
Why?
|
| Cell Survival | 1 | 2010 | 945 | 0.020 |
Why?
|
| Blotting, Northern | 1 | 2007 | 150 | 0.020 |
Why?
|
| Mice, Transgenic | 1 | 2009 | 665 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2007 | 197 | 0.020 |
Why?
|
| Arteries | 1 | 2007 | 81 | 0.020 |
Why?
|
| RNA | 1 | 2009 | 266 | 0.020 |
Why?
|
| Amino Acids | 1 | 2007 | 148 | 0.020 |
Why?
|
| Aged, 80 and over | 2 | 2004 | 2853 | 0.020 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2007 | 140 | 0.020 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 2005 | 1 | 0.010 |
Why?
|
| Syndecans | 1 | 2005 | 2 | 0.010 |
Why?
|
| ADAM Proteins | 1 | 2005 | 20 | 0.010 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2005 | 43 | 0.010 |
Why?
|
| Matrix Metalloproteinases | 1 | 2005 | 49 | 0.010 |
Why?
|
| Sialoglycoproteins | 1 | 2004 | 14 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 2004 | 54 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2005 | 92 | 0.010 |
Why?
|
| Dexamethasone | 1 | 2004 | 55 | 0.010 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2010 | 968 | 0.010 |
Why?
|
| Ovary | 1 | 2005 | 113 | 0.010 |
Why?
|
| Osteopontin | 1 | 2004 | 46 | 0.010 |
Why?
|
| Cell Count | 1 | 2004 | 145 | 0.010 |
Why?
|
| Materials Testing | 1 | 2004 | 101 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2004 | 283 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2005 | 224 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 287 | 0.010 |
Why?
|
| Phalloidine | 1 | 2003 | 1 | 0.010 |
Why?
|
| Rhodamines | 1 | 2003 | 22 | 0.010 |
Why?
|
| Micromanipulation | 1 | 2003 | 12 | 0.010 |
Why?
|
| Base Sequence | 1 | 2005 | 983 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2004 | 490 | 0.010 |
Why?
|
| Cytoskeleton | 1 | 2003 | 114 | 0.010 |
Why?
|
| Mechanics | 1 | 2002 | 3 | 0.010 |
Why?
|
| Transducers | 1 | 2002 | 14 | 0.010 |
Why?
|
| Absorption | 1 | 2002 | 22 | 0.010 |
Why?
|
| Elasticity | 1 | 2002 | 53 | 0.010 |
Why?
|
| Tensile Strength | 1 | 2002 | 27 | 0.010 |
Why?
|
| Equipment Design | 1 | 2002 | 145 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2002 | 181 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2003 | 182 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2002 | 139 | 0.010 |
Why?
|
| Calcium | 1 | 2004 | 491 | 0.010 |
Why?
|
| Species Specificity | 1 | 2002 | 286 | 0.010 |
Why?
|
| Tissue Engineering | 1 | 2002 | 75 | 0.010 |
Why?
|
| Cell Differentiation | 1 | 2004 | 638 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2002 | 154 | 0.010 |
Why?
|
| Cattle | 1 | 2002 | 498 | 0.010 |
Why?
|
| Cell Membrane | 1 | 2003 | 403 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2002 | 611 | 0.010 |
Why?
|
| Aged | 2 | 2004 | 8214 | 0.010 |
Why?
|
| Water | 1 | 2002 | 316 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2005 | 1070 | 0.010 |
Why?
|
| Treatment Outcome | 1 | 2004 | 1604 | 0.010 |
Why?
|